@WHO: The test effectively checks for the presence of anti-SARS-CoV-2 antibodies developed either in response to an infection or to a vaccine. This represents the first test licence signed by @MedsPatentPool & included in WHO’s #COVID19 Technology Access Pool 👉https://t.co/0EwiiWiAw8 https://t.co/On0zNfLmTn

@WHO: The test effectively checks for the presence of anti-SARS-CoV-2 antibodies developed either in response to an infection or to a vaccine. This represents the first test licence signed by @MedsPatentPool & included in WHO’s #COVID19 Technology Access Pool 👉https://t.co/0EwiiWiAw8 https://t.co/On0zNfLmTn

http://twitter.com/WHO
via IFTTT

Comments